ZLDPF
Zealand Pharma A/S
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
50.51
▲ 0.51 (1.02%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
50.51
Prev close
50.00
Day high
50.00
Day low
50.00
Volume
330
Market cap
$3.44B
P/E (TTM)
8.27
52W range
35.93 – 83.12
Day trading desk
Gap from prior close
+1.02%
Prior close 50.00
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
50.51 – 50.51
Position in range
—
—
ATR (14D)
0.78
1.55% of price
Prior day high
50.00
PDH
Prior day low
50.00
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 781
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-4.13%
-2.8%
1M
+12.21%
+8.5%
3M
+3.31%
+0.2%
6M
-16.40%
-27.5%
YTD
-29.46%
-41.7%
1Y
-17.20%
-37.2%
3Y
+42.89%
-31.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ZLDPF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
368.20K
Total on file
Fundamentals
Market cap$3.44B
Enterprise value$-10.54B
Revenue (TTM)$4.64B
Gross profit$4.64B
EBITDA$2.32B
Net income$2.74B
EPS (TTM)$6.11
Free cash flow$-2.06B
Total cash$14.46B
Total debt$411.00M
Book value / share$40.53
Shares outstanding68.11M
Float55.43M
Short % of float—
Dividend yield—
Beta (5Y)0.60
Valuation & profitability ratios
Trailing P/E8.27
Forward P/E-43.54
PEG ratio—
Price / sales—
Price / book1.25
EV / revenue-2.27
EV / EBITDA-4.54
Gross margin100.00%
Operating margin85.93%
Profit margin59.02%
Return on equity16.31%
Return on assets7.81%
Debt / equity2.28
Current ratio13.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $9.21B | $62.69M | $342.79M | $103.99M | +14,598.9% |
| Operating revenue | $9.21B | $62.69M | $342.79M | $103.99M | +14,598.9% |
| Cost of revenue | $816.00K | $7.87M | $19.17M | $0 | -89.6% |
| Gross profit | $9.21B | $54.82M | $323.61M | $103.99M | +16,708.7% |
| Research & development | $1.60B | $919.87M | $684.90M | $614.04M | +74.4% |
| Selling, general & admin | $273.09M | $229.20M | $89.85M | $306.54M | +19.1% |
| Total operating expense | $2.10B | $1.32B | $900.83M | $920.59M | +58.7% |
| Operating income | $7.11B | -$1.27B | -$577.22M | -$816.60M | +660.5% |
| Net interest income | $271.64M | $128.74M | $16.34M | -$48.68M | +111.0% |
| Pre-tax income | $7.00B | -$1.08B | -$708.87M | -$972.04M | +746.2% |
| Tax provision | $546.06M | -$4.62M | -$5.13M | -$6.43M | +11,927.1% |
| Net income | $6.46B | -$1.08B | -$703.74M | -$1.20B | +698.3% |
| Net income to common | $6.46B | -$1.08B | -$703.74M | -$1.20B | +698.3% |
| Basic EPS | 91.56 | -16.24 | -12.44 | -26.02 | +663.8% |
| Diluted EPS | 90.22 | -16.24 | -12.44 | -26.02 | +655.5% |
| EBIT | $7.03B | -$1.05B | -$683.03M | -$915.59M | +769.9% |
| EBITDA | $7.06B | -$1.02B | -$657.95M | -$797.63M | +789.5% |
| Basic shares | 70.50M | 66.43M | 56.59M | 46.20M | +6.1% |
| Diluted shares | 71.55M | 66.43M | 56.59M | 46.20M | +7.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.58B | $726.03M | $449.31M | $1.07B | +530.3% |
| Cash & short-term investments | $15.11B | $8.23B | $1.63B | $1.18B | +83.7% |
| Accounts receivable | $336.00K | $499.00K | $97.80M | $115.62M | -32.7% |
| Inventory | $0 | $10.70M | $7.93M | $1.29M | -100.0% |
| Total current assets | $15.67B | $8.53B | $1.78B | $1.32B | +83.8% |
| Property, plant & equipment | $151.43M | $125.25M | $149.85M | $165.49M | +20.9% |
| Goodwill & intangibles | $44.97M | $12.62M | $12.26M | $0 | +256.3% |
| Total assets | $15.95B | $9.51B | $1.98B | $1.54B | +67.8% |
| Total current liabilities | $664.97M | $403.47M | $284.58M | $195.49M | +64.8% |
| Long-term debt | $302.92M | $285.33M | $0 | $320.74M | +6.2% |
| Total debt | $405.77M | $391.76M | $119.23M | $443.47M | +3.6% |
| Total liabilities | $1.12B | $888.86M | $387.15M | $723.89M | +25.8% |
| Retained earnings | $6.29M | -$6.16B | -$4.89B | -$4.17B | +100.1% |
| Shareholder equity | $14.83B | $8.62B | $1.59B | $815.91M | +72.1% |
| Working capital | $15.01B | $8.12B | $1.50B | $1.12B | +84.7% |
| Net tangible assets | $14.79B | $8.60B | $1.58B | $815.91M | +71.8% |
| Shares issued | 71.52M | 71.02M | 58.75M | 51.70M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $6.46B | -$1.08B | -$703.74M | -$1.20B | +698.3% |
| Depreciation & amortisation | $27.37M | $25.85M | $25.09M | $117.96M | +5.9% |
| Stock-based compensation | $115.89M | $87.03M | $61.43M | $52.29M | +33.2% |
| Change in working capital | $87.73M | $117.76M | $52.10M | $10.16M | -25.5% |
| Operating cash flow | $6.53B | -$930.82M | -$425.67M | -$942.31M | +801.7% |
| Capital expenditure | -$69.07M | -$13.15M | -$23.75M | -$11.71M | -425.3% |
| Investing cash flow | -$2.25B | -$7.31B | -$1.09B | $281.26M | +69.2% |
| Share buybacks | -$407.17M | -$351.83M | -$41.60M | $0 | -15.7% |
| Financing cash flow | -$378.18M | $8.29B | $907.01M | $587.50M | -104.6% |
| Free cash flow | $6.46B | -$943.96M | -$449.42M | -$954.02M | +784.7% |
| End cash position | $4.58B | $726.03M | $449.31M | $1.07B | +530.3% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $34.00M | $68.92M | $49.57M | $9.09B | $8.00M | -50.7% |
| Operating revenue | $34.00M | $68.92M | $49.57M | $9.09B | $8.00M | -50.7% |
| Cost of revenue | $0 | $0 | $0 | $410.00K | $0 | — |
| Gross profit | $34.00M | $68.92M | $49.57M | $9.09B | $8.00M | -50.7% |
| Research & development | $469.00M | $530.07M | $320.04M | $464.14M | $290.00M | -11.5% |
| Selling, general & admin | $104.00M | -$131.05M | $190.85M | $110.46M | $102.00M | +179.4% |
| Total operating expense | $573.00M | $425.46M | $510.89M | $749.45M | $392.00M | +34.7% |
| Operating income | -$539.00M | -$356.54M | -$461.32M | $8.34B | -$384.00M | -51.2% |
| Net interest income | $66.00M | $89.24M | $101.55M | $47.29M | $32.00M | -26.0% |
| Pre-tax income | -$394.00M | -$406.51M | -$366.73M | $8.11B | -$336.00M | +3.1% |
| Tax provision | $0 | -$27.39M | $37.50M | $537.32M | -$1.00M | +100.0% |
| Net income | -$394.00M | -$379.12M | -$404.23M | $7.57B | -$335.00M | -3.9% |
| Net income to common | -$394.00M | -$379.12M | -$404.23M | $7.57B | -$335.00M | -3.9% |
| Basic EPS | -5.58 | — | -5.75 | 107.08 | -4.74 | — |
| Diluted EPS | -5.58 | — | -5.75 | 105.61 | -4.74 | — |
| EBIT | -$389.00M | -$399.44M | -$359.74M | $8.12B | -$328.00M | +2.6% |
| EBITDA | -$379.00M | -$391.46M | -$352.51M | $8.13B | -$323.00M | +3.2% |
| Basic shares | 70.61M | — | 70.30M | 70.73M | 70.68M | — |
| Diluted shares | 70.61M | — | 70.30M | 71.71M | 70.68M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.85B | $4.58B | $5.97B | $7.24B | $776.15M | — | -15.9% |
| Cash & short-term investments | $14.47B | $15.11B | $16.17B | $16.58B | $8.54B | — | -4.2% |
| Accounts receivable | $5.00M | $336.00K | $6.78M | $2.17M | $8.08M | — | +1,388.1% |
| Inventory | — | $0 | $0 | $10.30M | $10.70M | $10.70M | — |
| Total current assets | $15.02B | $15.67B | $16.62B | $17.01B | $8.96B | — | -4.2% |
| Property, plant & equipment | $164.00M | $151.43M | $141.39M | $134.16M | $129.62M | — | +8.3% |
| Goodwill & intangibles | $45.00M | $44.97M | $12.73M | $13.59M | $14.14M | — | +0.1% |
| Total assets | $15.30B | $15.95B | $16.80B | $17.18B | $9.12B | — | -4.1% |
| Total current liabilities | $404.00M | $664.97M | $1.18B | $1.13B | $356.85M | — | -39.2% |
| Long-term debt | $307.00M | $302.92M | $298.45M | $294.00M | $289.78M | — | +1.3% |
| Total debt | $414.00M | $405.77M | $406.44M | $396.95M | $394.64M | — | +2.0% |
| Total liabilities | $832.00M | $1.12B | $1.63B | $1.57B | $813.74M | — | -25.6% |
| Retained earnings | -$356.00M | $6.29M | $355.04M | $803.23M | -$6.47B | — | -5,762.5% |
| Shareholder equity | $14.47B | $14.83B | $15.16B | $15.61B | $8.31B | — | -2.4% |
| Working capital | $14.61B | $15.01B | $15.44B | $15.89B | $8.60B | — | -2.6% |
| Net tangible assets | $14.42B | $14.79B | $15.15B | $15.60B | $8.29B | — | -2.4% |
| Shares issued | 71.53M | 71.52M | 71.36M | 71.34M | 71.05M | — | +0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$394.00M | -$379.12M | -$404.23M | $7.57B | -$335.00M | — | -3.9% |
| Depreciation & amortisation | $10.00M | $7.98M | $7.22M | $7.17M | $5.00M | — | +25.3% |
| Stock-based compensation | $32.00M | $30.36M | $30.81M | $31.72M | $23.00M | — | +5.4% |
| Change in working capital | -$280.00M | $525.15M | -$164.60M | -$91.83M | -$181.00M | — | -153.3% |
| Operating cash flow | -$672.00M | -$1.04B | -$443.77M | $8.52B | -$501.00M | — | +35.6% |
| Capital expenditure | -$11.00M | -$49.94M | -$3.64M | -$7.49M | -$8.00M | — | +78.0% |
| Investing cash flow | -$116.00M | -$373.44M | -$855.43M | -$1.57B | $555.00M | — | +68.9% |
| Share buybacks | — | $1.00K | -$74.76M | — | — | $0 | — |
| Financing cash flow | -$8.00M | $10.64M | -$78.28M | -$309.54M | -$1.00M | — | -175.2% |
| Free cash flow | -$683.00M | -$1.09B | -$447.42M | $8.51B | -$509.00M | — | +37.5% |
| End cash position | $3.85B | $4.58B | $5.97B | $7.24B | $776.00M | — | -15.9% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $119.12M | +140.3% |
| Next quarter | — | — | $616.03M | +793.9% |
| Current year | — | — | $4.84B | -47.5% |
| Next year | — | — | $4.06B | -16.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.53%
Held by institutions42.71%
Institutions holding164
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
50.81
-0.59% from price
SMA 20
48.99
+3.11% from price
SMA 50
46.34
+9.00% from price
SMA 100
47.12
+7.20% from price
SMA 200
56.27
-10.24% from price
EMA 12
49.90
+1.23% from price
EMA 26
48.66
+3.80% from price
EMA 50
47.80
+5.67% from price
RSI (14)
61.2
Neutral
MACD (12,26,9)
1.24
Hist -0.06
ATR (14)
0.78
1.55% of price
Realised vol 30D
32.1%
Annualised
Bollinger upper
53.48
20, 2σ
Bollinger lower
44.49
20, 2σ
50 / 200 cross
Death
46.34 vs 56.27
Trend bias
Below 200
-10.24%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.71
Less volatile than market
Correlation to SPY
0.15
Largely independent
Realised vol 30D
32.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-53.1%
Peak to trough
Max drawdown 5Y
-72.5%
Peak to trough
ATR 14
0.78
1.55% of price
Beta (reported)
0.60
5Y monthly, from filing
Headlines
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
GlobeNewswire · 6d ago
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
BioPharma Dive · 9d ago
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
Zacks · 10d ago
Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run
Simply Wall St. · 10d ago
Zealand Pharma Announces Financial Results for the First Half of 2026
GlobeNewswire · 10d ago
Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate
Simply Wall St. · 11d ago
Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million
GlobeNewswire · 11d ago
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
GlobeNewswire · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.